Patents by Inventor Roel P. Funke

Roel P. Funke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MAP3Ks as modifiers of the p53 pathway and methods of use
    Patent number: 8268548
    Abstract: Human MAP3K genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MAP3K are provided.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: September 18, 2012
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danix Li, Roel P. Funke
  • Marks as modifiers of the p53 pathway and methods of use
    Patent number: 8153384
    Abstract: Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: April 10, 2012
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Helen Francis-Lang, Danxi Li, Roel P. Funke, Marcia Belvin, Mario N. Lioubin
  • HPRP4s modifiers of the p53 pathway and methods of use
    Patent number: 7993829
    Abstract: Human hPRP4 genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of hPRP4 are provided.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: August 9, 2011
    Assignee: Exelixis Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Tak Hung, Helen Francis-Lang, Danix Li, Roel P. Funke, Michael Costa
  • GFATS as Modifiers of the P53 Pathway and Methods of Use
    Publication number: 20110159508
    Abstract: Human GFAT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of GFAT are provided.
    Type: Application
    Filed: October 7, 2010
    Publication date: June 30, 2011
    Applicant: EXELIXIS, INC.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke
  • Marks as modifiers of the p53 pathway and methods of use
    Publication number: 20100325743
    Abstract: Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided.
    Type: Application
    Filed: June 10, 2010
    Publication date: December 23, 2010
    Applicant: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke, Mario N. Lioubin
  • HADHs as Modifiers of the p21 Pathway and Methods of Use
    Publication number: 20100275275
    Abstract: Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided.
    Type: Application
    Filed: August 5, 2009
    Publication date: October 28, 2010
    Applicant: EXELIXIS INC.
    Inventors: Lori Friedman, Gregory D. Plowman, Roel P. Funke, Marcia Belvin, Danxi Li, Stephanie A. Robertson
  • MAP3Ks as modifiers of the p53 pathway and methods of use
    Publication number: 20090068186
    Abstract: Human MAP3K genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MAP3K are provided.
    Type: Application
    Filed: April 18, 2007
    Publication date: March 12, 2009
    Applicant: Exelixis Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke
  • SPHKS as modifiers of the p53 pathway and methods of use
    Publication number: 20080241131
    Abstract: Human SPHK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SPHK are provided.
    Type: Application
    Filed: April 3, 2008
    Publication date: October 2, 2008
    Applicant: Exelixis Inc.
    Inventors: Lori S. Friedman, Gregory D. Plowman, Michael R. Costa, Danxi Li, Roel P. Funke, Tak Hung
  • MARKs as Modifiers of the p53 Pathway and Methods of Use
    Publication number: 20080166709
    Abstract: Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided.
    Type: Application
    Filed: January 28, 2007
    Publication date: July 10, 2008
    Applicant: EXELIXIS, INC.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke, Mario N. Lioubin
  • PRMTs as modifiers of the p53 pathway and methods of use
    Patent number: 7049088
    Abstract: Human PRMT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of PRMT are provided.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: May 23, 2006
    Assignee: Exelixis, INC
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke, Rolf Peter Ryseck, Lata Jayaraman, David K. Bol, Matthew Lorenzi
  • HADHs as modifiers of the p21 pathway and methods of use
    Patent number: 6927022
    Abstract: Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: August 9, 2005
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Roel P. Funke, Marcia Belvin, Danxi Li, Stephanie A. Robertson
  • RRP sequences and knockout mice and uses thereof
    Publication number: 20030165497
    Abstract: RRP genes are identified as modulators of the p53 or p21 pathway, and thus are therapeutic targets for disorders associated with defective p53 or p21 function. Methods for identifying modulators of p53 or p21, comprising screening for agents that modulate the activity of RRP are provided. Modulating agents identified using the methods of the invention can be used to specifically inhibit growth of tumor cells that overexpress an RRP protein. mRRP1 knockout mice are also provided.
    Type: Application
    Filed: January 23, 2002
    Publication date: September 4, 2003
    Inventors: Mario N. Lioubin, Lori Friedman, Marcia Belvin, Jeffrey S. Larson, Changyou Chen, Stephanie A. Robertson, Wen Shi, Jocelyn Chan, Danxi Li, Helen Francis-Lang, Gregory D. Plowman, Roel P. Funke, Michael Schoor, Branko Zevnik, Gunther Kauselmann, Hartmut Tintrup
  • MARKs as modifiers of the p53 pathway and methods of use
    Publication number: 20030165809
    Abstract: Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: September 4, 2003
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke, Mario N. Lioubin
  • LRRCAPs as modifiers of the p53 pathway and methods of use
    Publication number: 20030138431
    Abstract: Human LRRCAPS genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of LRRCAPS are provided.
    Type: Application
    Filed: October 21, 2002
    Publication date: July 24, 2003
    Inventors: Marcia Belvin, Lothar Schleithoff, Gregory D. Plowman, Roel P. Funke, Mario N. Lioubin, Danxi Li, Helen Francis-Lang
  • IGs as modifiers of the p53 pathway and methods of use
    Publication number: 20030087266
    Abstract: Human IG genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of IG are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: May 8, 2003
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke, Mario N. Lioubin
  • CADs as modifiers of the p53 pathway and methods of use
    Publication number: 20030036076
    Abstract: Human CAD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of CAD are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: February 20, 2003
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke
  • P5CRs as modifiers of the p53 pathway and methods of use
    Publication number: 20030036078
    Abstract: Human P5CR genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of P5CR are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: February 20, 2003
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke, Stefan Engst
  • HPRP4s as modifiers of the p53 pathway and methods of use
    Publication number: 20030027230
    Abstract: Human hPRP4 genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of hPRP4 are provided.
    Type: Application
    Filed: August 2, 2002
    Publication date: February 6, 2003
    Inventors: Lori Friedman, Gregory D. Plowman, Tak Hung, Helen Francis-Lang, Danxi Li, Roel P. Funke, Michael Costa
  • SLC7s as modifiers of the p53 pathway and methods of use
    Publication number: 20030027188
    Abstract: Human SLC7 genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SLC7 are provided.
    Type: Application
    Filed: June 5, 2002
    Publication date: February 6, 2003
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke
  • HADHs as modifiers of the p21 pathway and methods of use
    Publication number: 20030022222
    Abstract: Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided.
    Type: Application
    Filed: July 10, 2002
    Publication date: January 30, 2003
    Inventors: Lori Friedman, Gregory D. Plowman, Roel P. Funke, Marcia Belvin, Danxi Li, Stephanie A. Robertson